Aviceda Therapeutics Inc.
Aviceda Therapeutics is a late-stage biotechnology company focused on harnessing immune cell checkpoints to develop innovative therapeutics for diseases characterized by chronic inflammation, including age-related macular degeneration, geographic atrophy, diabetic retinopathy, and other inflammatory and neurodegenerative conditions. The company leverages its proprietary HALOS™ nanotechnology platform to modulate immune responses and target disease pathways. Their research centers on glyco-immunology, immune checkpoint modulation, and nanotechnology to develop therapeutics for retinal and neurodegenerative diseases, collaborating with research institutions worldwide.
Industries
Nr. of Employees
small (1-50)
Aviceda Therapeutics Inc.
One Broadway, 14th Floor, Cambridge, MA 02142
Products
Intravitreal glycomimetic nanoparticle therapeutic (lead ophthalmic asset)
Biodegradable glycan-decorated nanoparticle formulated for intravitreal injection with a dual mechanism: repolarization of activated macrophages and inhibition of complement cascade amplification to slow lesion growth in geographic atrophy.
Glycomimetic nanoparticle candidates for diabetic macular edema and diabetic retinopathy
Glycan-coated nanoparticle therapeutics designed to reduce neutrophil and macrophage activation, inhibit NETosis, and reduce inflammatory mediators driving diabetic retinal disease.
Intravitreal glycomimetic nanoparticle therapeutic (lead ophthalmic asset)
Biodegradable glycan-decorated nanoparticle formulated for intravitreal injection with a dual mechanism: repolarization of activated macrophages and inhibition of complement cascade amplification to slow lesion growth in geographic atrophy.
Glycomimetic nanoparticle candidates for diabetic macular edema and diabetic retinopathy
Glycan-coated nanoparticle therapeutics designed to reduce neutrophil and macrophage activation, inhibit NETosis, and reduce inflammatory mediators driving diabetic retinal disease.
Services
Design and conduct of randomized Phase 2/3 ophthalmology trials including patient enrollment, safety and efficacy assessment, pharmacokinetics, and active-comparator arms.
Preclinical pharmacology, mechanism-of-action studies, ocular and systemic safety evaluations, and IND-enabling toxicology in non-rodent species to support regulatory filings.
Preparation and submission support for regulatory filings (IND and related requests) and guidance on regulatory pathways to support clinical development.
Establishing and managing collaborations with academic centers and specialized research groups in glycobiology and related disciplines to accelerate discovery and translation.
Planning and operational support for chemistry, manufacturing and controls (CMC) development and clinical manufacturing scale-up of complex therapeutics, informed by leadership experience.
Design and conduct of randomized Phase 2/3 ophthalmology trials including patient enrollment, safety and efficacy assessment, pharmacokinetics, and active-comparator arms.
Preclinical pharmacology, mechanism-of-action studies, ocular and systemic safety evaluations, and IND-enabling toxicology in non-rodent species to support regulatory filings.
Preparation and submission support for regulatory filings (IND and related requests) and guidance on regulatory pathways to support clinical development.
Establishing and managing collaborations with academic centers and specialized research groups in glycobiology and related disciplines to accelerate discovery and translation.
Planning and operational support for chemistry, manufacturing and controls (CMC) development and clinical manufacturing scale-up of complex therapeutics, informed by leadership experience.
Expertise Areas
- Glyco-immunology and sialic-acid mimetic therapeutics
- Ophthalmology drug development for geographic atrophy and retinal vascular disease
- Nanoparticle drug delivery and intravitreal formulation
- Proteogenomic biomarker discovery
Key Technologies
- Sialic-acid mimetic ligands
- Glycan-coated biodegradable nanoparticles
- Intravitreal drug delivery
- Proteogenomic analysis
News & Updates
Aviceda announced the appointment of Dr. Cunningham to its Board of Directors, bringing expertise in ophthalmology, immunology, and therapeutic innovation.
Dr. Nau joins as CEO to lead the company's next phase of growth and innovation, with a focus on immunomodulation therapies.
The company secured funding to advance its lead program AVD-104 for geographic atrophy into pivotal trials.
The company appointed Dr. Cunningham, an ophthalmology and immunology expert, to its board.
Industry veteran Dr. Nau is appointed to lead the company into its next growth phase.
Funding will support pivotal trials for AVD-104 in geographic atrophy.
Aviceda announced the appointment of Dr. Cunningham to its Board of Directors, bringing expertise in ophthalmology, immunology, and therapeutic innovation.
Dr. Nau joins as CEO to lead the company's next phase of growth and innovation, with a focus on immunomodulation therapies.
The company secured funding to advance its lead program AVD-104 for geographic atrophy into pivotal trials.
The company appointed Dr. Cunningham, an ophthalmology and immunology expert, to its board.
Industry veteran Dr. Nau is appointed to lead the company into its next growth phase.
Funding will support pivotal trials for AVD-104 in geographic atrophy.